LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

Home・Listă Acțiuni・Incyte Corp

Incyte Corp

Deschisă

SectorSănătate

95.35 -0.22

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

93.78

Maxim

95.43

Indicatori cheie
By Trading Economics
Venit	4.1M 303M
Vânzări	-234M 1.3B
P/E Medie Sector	14.17 51.415
EPS	1.81
Marjă de profit	23.834
Angajați	2,844
EBITDA	-47M 367M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+14.5% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	993M 20B
Deschiderea anterioară	95.57
Închiderea anterioară	95.35

Sentimentul știrilor

By Acuity

46%

54%

145 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

59.52 / 62.66 Suport & Rezistență

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 mai 2026, 23:10 UTC

Acțiuni populare

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principalele dinamici ale pieței

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Câștiguri

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Câștiguri

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Câștiguri

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Achiziții, Fuziuni, Preluări

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Achiziții, Fuziuni, Preluări

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Vinci Buys Canada's Modern Group of Companies

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

14.5% sus

Prognoză pe 12 luni

Medie 109.13 USD 14.5%

Maxim 135 USD

Minim 75 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

145 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation